Adamas Pharmaceuticals, Inc. engages in the development and commercialization of controlled release combination therapeutics to treat healthcare problems, primarily in the areas of infectious diseases and central nervous system disorders. It also develops novel extended release and combination products for symptomatic treatment of dementia. The company was incorporated in 2000 and is headquartered in Emeryville, California with operations in India, the United States, and Singapore.

Research Grants 4 show all


$337.5K
2012

$128.6K
2013

$509.3K
2014

$483.2K
2015

Patents 169show all

  • 71
    A61K - Preparations for medical, dental, or toilet purposes
  • 4
    C07C - Acyclic or carbocyclic compounds
  • 2
    G06Q - Data processing systems or methods, specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes
  • 2
    Y02A - Technologies for adaptation to climate change

Clinical Trials 18show all

12Phase 33Phase 21N/A1Phase 11Phase 2/Phase 3

SEC Filings show all


65
8-K

18
10-Q

6
10-K

1
D

1
S-1

Contact Information

1900 Powell Street Suite 1050
Emeryville, CA 94608
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$82,000,00011-502009-10-01Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2005-05-01$21,000,000Series BMohr Davidow Ventures
2007-08-06$13,000,000Series C
2009-10-01$40,000,000Series DMohr Davidow Ventures, Northgate Capital, Aeris Capital, DAG Ventures
2008-07-17$8,000,000Series C

SEC Form D Funding Events

DateOfferedSoldType
2007-08-06Unknown Unknown Other (Paper Filing)